Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A comparison of the effects of Sevoflurane and Isoflurane on cardiovascular parameters measured by cardiac magnetic resonance imaging in paediatric patients with congenital heart disease. A randomised controlled trial.
ISRCTN ISRCTN81324728
ClinicalTrials.gov identifier
Public title A comparison of the effects of Sevoflurane and Isoflurane on cardiovascular parameters measured by cardiac magnetic resonance imaging in paediatric patients with congenital heart disease. A randomised controlled trial.
Scientific title
Acronym N/A
Serial number at source N0013145919
Study hypothesis Sevoflurane and isoflurane are commonly used to anaesthetise patients with congenital heart disease. Which agent causes the least depression of cardiac function?
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Heart disease
Participants - inclusion criteria Subjects will be children with congenital cardiac abnormalities who are undergoing magnetic resonance imaging to achieve an accurate diagnosis and determine future treatment options.
Participants - exclusion criteria 1. Patient or parental refusal
2. Allergic, anaphylactic or other reactions to inhalational anaesthetic agents
3. Patients older than 16 years of age.
Anticipated start date 01/09/2003
Anticipated end date 01/09/2004
Status of trial Completed
Patient information material
Target number of participants 10
Interventions The routine study usually lasts 1 hour. For the first 30 minutes, each subject will be anaesthetised with one of the agents. The agent will then be swapped and the patients anaesthetised with the other agent for the remaining 30 minutes. Variables will be recorded at the end of each period.
Primary outcome measure(s) Cardiac output, aortic and pulmonary blood flow, arterial pressure, systemic vascular resistance.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Guy's and St. Thomas' NHS Foundation Trust (UK) Own account, NHS R&D Support Funding
Trial website
Publications 2008 results on http://www.ncbi.nlm.nih.gov/pubmed/18346608
Contact name Dr  Priti  Dalal
  Address Theatres
2nd Floor, New Guy House
Guy's Hospital
St Thomas' Street
  City/town London
  Zip/Postcode SE1 9RT
  Country United Kingdom
Sponsor Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2005
Last edited 15/07/2009
Date ISRCTN assigned 30/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central